{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:35:41Z","timestamp":1793205341984,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.phrs.2021.105859","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T14:25:25Z","timestamp":1630160725000},"page":"105859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2212 New perspectives for combination therapy"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7528","authenticated-orcid":false,"given":"Peter","family":"Kolkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-0990","authenticated-orcid":false,"given":"Ulrich","family":"Kintscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105859_bib1","first-page":"515","article-title":"Production of nephrosclerosis by overdosage with desoxycorticosterone acetate","volume":"47","author":"Selye","year":"1942","journal-title":"Can. Med. Assess. J."},{"key":"10.1016\/j.phrs.2021.105859_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1126\/science.121.3141.368","article-title":"Anticortisol action of aldosterone","volume":"121","author":"Selye","year":"1955","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105859_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pharmthera.2005.07.006","article-title":"CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets","volume":"111","author":"Hakki","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105859_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.hjh.0000226183.98439.b3","article-title":"Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?","volume":"24","author":"M\u00e9nard","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2021.105859_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/1097-0142(19900315)65:6<1279::AID-CNCR2820650604>3.0.CO;2-3","article-title":"A phase I trial of CGS 16949A. A new aromatase inhibitor","volume":"65","author":"Lipton","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2021.105859_bib6","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2021.105859_bib8","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.0c00233","article-title":"Discovery of 3-pyridyl isoindolin-1-one derivatives as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105859_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105859_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.phrs.2021.105859_bib11","doi-asserted-by":"crossref","first-page":"012","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.phrs.2021.105859_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2021.105859_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.phrs.2021.105859_bib14","doi-asserted-by":"crossref","first-page":"T83","DOI":"10.1530\/JOE-17-0155","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor null mice: informing cell-type-specific roles","volume":"234","author":"Cole","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105859_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41371-020-0386-5","article-title":"Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart","volume":"35","author":"Young","year":"2021","journal-title":"J. Hum. Hypert."},{"key":"10.1016\/j.phrs.2021.105859_bib16","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2021.105859_bib17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease","volume":"25","author":"Huang","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2021.105859_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00424-017-1950-x","article-title":"The role of macrophages in hypertension and its complications","volume":"469","author":"Rucker","year":"2017","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.phrs.2021.105859_bib19","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2021.105859_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/HYPERTENSIONAHA.112.198986","article-title":"Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo","volume":"61","author":"Messaoudi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105859_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.111.187872","article-title":"Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system","volume":"59","author":"Latouche","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105859_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105859_bib23","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 years of the mineralocorticoid receptor: nongenomic effects via the mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105859_bib24","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1681\/ASN.2018101025","article-title":"Rapid aldosterone-mediated signaling in the DCT increases activity of the thiazide-sensitive NaCl cotransporter","volume":"30","author":"Cheng","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2021.105859_bib25","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"G\u00fcder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105859_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurjhf\/hfr129","article-title":"Aldosterone and cortisol predict medium-term left ventricular remodeling following myocardial infarction","volume":"13","author":"Weir","year":"2011","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2021.105859_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105859_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tem.2004.03.006","article-title":"Is aldosterone bad for the heart?","volume":"15","author":"Funder","year":"2004","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2021.105859_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets","volume":"22","author":"Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2021.105859_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: new insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annu Rev. Pharm. Toxicol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","article-title":"Role of mineralocorticoid receptor antagonists in cardiovascular disease","volume":"116","author":"Ferrario","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2021.105859_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypert. Res."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib35","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105859_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2021.105859_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105859_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105859_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr. Opin. Pharm."},{"issue":"14","key":"10.1016\/j.phrs.2021.105859_bib42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Eplerenone, a selective aldosterone blocker, inpatients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105859_bib44","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"REMINDER Investigators, Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib45","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"ALBATROSS investigators, early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105859_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: the MINIMIZE STEMI trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"HOMAGE (Heart Omics in AGEing) consortium, proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.phrs.2021.105859_bib48","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.0000140973.60992.9A","article-title":"Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis","volume":"110","author":"Querejeta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105859_bib49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2013.10.006","article-title":"Developing therapies for heart failure with preserved ejection fraction: current state and future directions","volume":"2","author":"Butler","year":"2014","journal-title":"JACC Heart Fail."},{"issue":"15","key":"10.1016\/j.phrs.2021.105859_bib51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11897-017-0336-x","article-title":"Designing future clinical trials in heart failure with preserved ejection fraction: lessons from TOPCAT","volume":"14","author":"Patel","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.phrs.2021.105859_bib53","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Hemodialysis Novel Therapies Consortium, Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib54","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2021.105859_bib55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.kint.2018.12.006","article-title":"The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward","volume":"95","author":"Rossignol","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2021.105859_bib56","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105859_bib57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2019.04.023","article-title":"Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: rationale and design of the ALDOCURE trial","volume":"214","author":"Alexandre","year":"2019","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13054-020-03055-6","article-title":"Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease","volume":"24","author":"Liaudet","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105859_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/FJC.0000000000000960","article-title":"Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?","volume":"77","author":"Wilcox","year":"2020","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.phrs.2021.105859_bib60","first-page":"4","article-title":"Results of open-label non-randomized comparative clinical trial: \"BromhexIne and Spironolactone for CoronvirUs Infection requiring hospiTalization (BISCUIT)","volume":"60","author":"Mareev","year":"2020","journal-title":"Kardiologiia"},{"key":"10.1016\/j.phrs.2021.105859_bib61","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/jcm9092943","article-title":"The efficacy of the mineralcorticoid receptor antagonist canrenone in COVID-19 patients","volume":"9","author":"Vicenzi","year":"2020","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","article-title":"Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease","volume":"26","author":"Dojki","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","article-title":"Mitigating risk of aldosterone in diabetic kidney disease","volume":"29","author":"Frimodt-M\u00f8ller","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a nonsteroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105859_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.604928","article-title":"The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury","volume":"12","author":"Jaisser","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105859_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2021.105859_bib70","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.jmedchem.8b01523","article-title":"Identification of mineralocorticoid receptor modulators with low impact on electrolyte homeostasis but maintained organ protection","volume":"62","author":"Granberg","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105859_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13543784.2017.1274732","article-title":"Discontinued drug therapies to treat diabetes in 2015","volume":"26","author":"Hedrington","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/1470320319827449","article-title":"The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone","volume":"20","author":"Bamberg","year":"2019","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpdd.855","article-title":"Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers","volume":"10","author":"Nakamura","year":"2021","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.phrs.2021.105859_bib76","series-title":"Hepatol. Res.","article-title":"Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: a randomized controlled study","author":"Okanoue","year":"2021"},{"key":"10.1016\/j.phrs.2021.105859_bib77","unstructured":"\u3008https:\/\/www.mt-pharma.co.jp\/e\/develop\/pipeline.html\u3009."},{"key":"10.1016\/j.phrs.2021.105859_bib78","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2021.105859_bib79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J. Hum. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2021.105859_bib80","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.phrs.2021.105859_bib81","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2021.105859_bib82","article-title":"Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: a post hoc analysis of the ESAX-HTN study","author":"Kario","year":"2020","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.phrs.2021.105859_bib84","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib85","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/biomedicines9050549","article-title":"Characterization of direct perturbations on voltage-gated sodium current by esaxerenone, a nonsteroidal mineralocorticoid receptor blocker","volume":"9","author":"Chang","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.phrs.2021.105859_bib86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur. J. Heart Fail"},{"issue":"6","key":"10.1016\/j.phrs.2021.105859_bib87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"11","key":"10.1016\/j.phrs.2021.105859_bib88","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2021.105859_bib89","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JOE-17-0060","article-title":"30 years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity","volume":"234","author":"Fuller","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105859_bib90","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"36","key":"10.1016\/j.phrs.2021.105859_bib91","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib93","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.phrs.2021.105859_bib94","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2021.105859_bib95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-mineralocorticoid receptor pathway contributes to renal injury in salt-loaded db\/db mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105859_bib96","doi-asserted-by":"crossref","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","author":"Droebner","year":"2021","journal-title":"Am. J. Nephrol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105859_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105859_bib98","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2021.105859_bib99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharm."},{"key":"10.1016\/j.phrs.2021.105859_bib100","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20203110S1238b","article-title":"Uncovering genomic alterations in DOCA-salt nephropathy rats treated with Finerenone","volume":"31","author":"Wu","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"31","key":"10.1016\/j.phrs.2021.105859_bib101","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib102","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone \u2212 results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Filippatos; on behalf of the FIDELIO-DKD study investigators, design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. FIDELIO-DKD study investigators","volume":"50","author":"Bakris","year":"2019","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105859_bib104","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2021.105859_bib105","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","author":"Agarwal","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"issue":"23","key":"10.1016\/j.phrs.2021.105859_bib106","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105859_bib107","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2021.105859_bib108","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105859_bib109","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105859_bib110","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110956","article-title":"FIGARO-DKD Investigators, Cardiovascular events with finerenone in kidney disease and type 2 diabetes","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105859_bib111","unstructured":"\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf\u3009."},{"issue":"15","key":"10.1016\/j.phrs.2021.105859_bib112","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2021.105859_bib113","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105859_bib114","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105859_bib115","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2042098615589905","article-title":"Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function","volume":"6","author":"Esteras","year":"2015","journal-title":"Ther. Adv. Drug Saf."},{"issue":"10","key":"10.1016\/j.phrs.2021.105859_bib116","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2021.105859_bib117","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev. Physiol."},{"issue":"15","key":"10.1016\/j.phrs.2021.105859_bib118","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced trial investigators, cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2021.105859_bib119","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial committees and investigatorsdapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105859_bib120","first-page":"1","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2021.105859_bib121","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF","volume":"41","author":"Kristensen","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105859_bib122","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2021.105859_bib123","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3803\/EnM.2021.987","article-title":"Cardiorenal protection in diabetic kidney disease","volume":"36","author":"Lee","year":"2021","journal-title":"Endocrinol. Metab. (Seoul. )"},{"key":"10.1016\/j.phrs.2021.105859_bib124","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2021. Oslo, Norway. ISSN 1726\u20134898. ISBN 978\u201382-8406\u2013165-8."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:34:20Z","timestamp":1760913260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":124,"alternative-id":["S1043661821004436"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105859","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2212 New perspectives for combination therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105859"}}